Medtech Accelerator Sofinnova MD Start III Launches a Call for Early Stage Medical Device Projects
8.6.2021 19:00:00 EEST | Business Wire | Press release
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today that its medtech accelerator, Sofinnova MD Start III, is launching a call for early-stage projects. Sofinnova MD Start III is part of the Sofinnova platform of funds and actively works with clinicians and entrepreneurs to develop disruptive therapeutic medical devices. This call for projects aims to award funding and mentorship to selected projects through the MDS III accelerator program. Proposals will be accepted until July 9th, 2021 via the online application form.
The Sofinnova MD Start III Fund recently raised over €50 million from key institutional and corporate investors and is managed by a dedicated team of serial entrepreneurs and clinicians. The fund’s goal is to transform innovative ideas into medical realities by creating and building world-class medical device companies dedicated to the development of novel therapeutic medical devices and procedures. To date, the fund has created 10 companies and reviewed over 2000 projects.
Sofinnova MD Start III has privileged access to breakthrough technologies in healthcare through its network of scientists and experts from the top research and development centers around the world. This call for proposals aims to build on the fund’s existing deal flow to enable greater access to funding and support to promising early-stage projects or companies with a strong clinical impact and a high potential to improve patient lives.
Selected projects will receive financial contribution through a maturation grant or an investment from the Sofinnova MD Start III Fund, as well as operational support, in line with the model of the accelerator as a hands-on, joint project development with inventors.
Anne Osdoit, Partner at Sofinnova Partners and a key member of the Sofinnova MD Start III Fund team, said “We are looking for the most promising cutting edge therapeutic projects in the medical device sector. With our strong operational, financial and strategic expertise as well as our vast industry network, we are able to provide the key components to successfully build companies that will advance patient care and medtech innovation.”
The review and selection process will be conducted by the Sofinnova MD Start III team, which consists of medical, scientific and engineering professionals, with extensive experience in medtech entrepreneurship and a strong network of stakeholders across the industry, corporate partners, and investors.
Sofinnova MD Start III builds on the success of MD Start I and MD Start II in creating and accelerating companies that offer revolutionary solutions for unmet medical needs, bridging the gap between patient care and medical device innovation.
###
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: www.sofinnovapartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005876/en/
Contact information
Media:
Bommy Lee
Head of Communications, Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneyco.com
+1 212 223 0561
France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
Italy
Havas PR Milan
Rafaella Casula
rafaella.casula@havaspr.com
+39 (0) 345 3780834
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Interactive Brokers Expands AI Integration Capabilities – Adding ChatGPT and Grok to Its Growing Suite of Agentic Trading Tools22.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the expansion of its agentic trading capabilities with the addition of ChatGPT and Grok, further broadening a growing ecosystem of AI platform integrations that began with Claude. Available through certified AI connector marketplaces across multiple leading platforms, these integrations allow clients to research, analyze, and generate instructions with speed and efficiency to uncover new trading and investing opportunities instantly. With this release, Interactive Brokers also extends the selection of products available for order instructions to include support for options, futures and futures options in addition to equities and ETFs. “We continue to see growing interest from investors in using artificial intelligence as a more natural way to interact with financial markets,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “Adding ChatGPT and Grok, together with support for options and fut
IQM Named Among Quantum Collaborators in HPE's New Hybrid Quantum-HPC Platform22.6.2026 16:22:00 EEST | Press release
Hewlett Packard Enterprise has named IQM Quantum Computers among the companies collaborating on its hybrid classical-quantum computing platform, announced at HPE Discover Las Vegas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622035759/en/ IQM Radiance quantum computer at HPE Discover Las Vegas 2026 IQM, a global leader in full-stack superconducting quantum computers, is contributing superconducting quantum processor technology to the effort, in which HPE is integrating multiple quantum modalities with its Cray supercomputing infrastructure. This collaboration strengthens IQM's global expansion plans as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). For IQM, HPE's selection places the company at the center of one of the computing industry's most significant efforts to bring quantum and high-performance computing together, an integration widely rega
Return Abuse Goes Mainstream as Nearly Half of Consumers Use AI in Return Claims, New Riskified Research Finds22.6.2026 15:30:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, today released a new global report, “Rewriting the Rules on Returns”, exploring how consumer attitudes and behaviors around ecommerce returns are evolving in the age of artificial intelligence (AI). The Riskified-commissioned study, conducted by eTail Insights, is based on a survey of 2,091 consumers across seven countries, alongside in-depth interviews with senior leaders from many of the largest retail companies in the world. The research finds that return abuse behaviors are increasingly normalized, while nearly half of consumers already use generative AI tools to assist with return or refund claims. At the same time, merchants are responding by tightening return policies, shortening return windows, and deploying advanced AI detection to better distinguish between legitimate behavior and abuse patterns. Key Findings Nearly half of consumers (50%) report using generative AI tools such as ChatG
Forrester Unveils Agendas For 2026 Technology & Innovation Forums In North America And EMEA22.6.2026 15:00:00 EEST | Press release
Forrester (Nasdaq: FORR) today announced the full conference agendas for its Technology & Innovation Forum Central (Austin, September 14–15, 2026), Technology & Innovation Forum EMEA (London, September 30–October 1, 2026), and Technology & Innovation Forum East (New York City, November 4–5, 2026). This year’s theme, “The IT Singularity,” dives into the new AI era in which AI has become ubiquitous and no longer a competitive advantage on its own. To succeed, technology leaders including chief information officers, chief data officers, and chief AI officers need to integrate AI into their operating models, modernize software development and IT operations, strengthen data and governance practices, and align technology investments with business strategy. Across the Forums, tech leaders and their teams will learn how to scale AI responsibly, accelerate delivery, and strengthen executive confidence in an increasingly autonomous, AI-driven environment. Key sessions include: The AI Voyage — Fr
AdvanCell Establishes U.S. Global Headquarters and Secures Flagship Manufacturing Facility in Greater Boston to Drive Growth Strategy22.6.2026 15:00:00 EEST | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the establishment of its U.S. Global Headquarters in the Greater Boston area, and the lease of a new 128,000-square-foot facility that will become the Company’s U.S. flagship manufacturing center supporting its long-term growth and commercialization strategy. The expansion marks an important milestone in the Company’s evolution into a U.S.-based radiopharmaceutical company with integrated operations spanning North America and Australia. The investment reflects AdvanCell's strategy to expand its U.S. presence and build the infrastructure needed to support the development and future commercialization of ADVC001 and its Lead-212 targeted alpha therapy pipeline. Located in Greater Boston, the Innovation Park campus owned by IQHQ provides access to a world-class life-science ecosystem, supporting the next phase of the Company’s growth. The Andover facility will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom